Melenor

Risedronate sodium, the active ingredient in Melenor, is a bisphosphonate presented as an oral tablet for oral use in the European market. It treats postmenopausal and male osteoporosis as well as Paget's disease of bone, helping to reduce bone loss and fracture risk.

GNH USA supplies Melenor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, transplant centres and oncology centres worldwide, providing reliable sourcing for regulated markets. The company adheres to stringent quality standards and offers comprehensive logistics support.

Risedronate sodium is a bisphosphonate used to manage disorders of bone remodeling.

- Postmenopausal osteoporosis: increases bone mineral density and reduces risk of vertebral and non‑vertebral fractures. - Male osteoporosis: improves bone strength and lowers fracture incidence in men with low bone mass. - Paget's disease of bone: normalizes accelerated bone turnover and alleviates associated pain.

Risedronate sodium may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Abdominal pain - Nausea - Dyspepsia - Constipation - Musculoskeletal pain - Headache

Serious or Rare Side Effects: - Osteonecrosis of the jaw - Atypical femur fracture - Severe esophageal ulceration or erosion - Acute-phase reaction with fever and myalgia - Severe hypocalcemia - Anaphylactic or severe allergic reaction

Before prescribing risedronate sodium, clinicians should consider several precautionary measures to ensure safe use.

- Renal function: assess glomerular filtration rate and avoid use in severe renal impairment. - Calcium and vitamin D status: ensure adequate supplementation to reduce hypocalcemia risk. - Esophageal disorders: contraindicated in patients with active esophageal inflammation or stricture. - Concomitant corticosteroid therapy: monitor for increased risk of gastrointestinal complications. - Pregnancy and lactation: safety not established; avoid use unless benefits outweigh potential risks. - Store below 25°C: keep in the original packaging, protect from moisture and light.

Risedronate sodium can interact with other medicines, affecting its absorption or increasing adverse effect risk.

Major Interactions (Avoid): - Calcium, magnesium or iron supplements taken concurrently: markedly reduce risedronate absorption. - Antacids containing aluminum or magnesium: interfere with drug uptake and should be spaced at least 30 minutes apart. - Oral corticosteroids: increase risk of gastrointestinal ulceration when combined.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect; monitor INR regularly. - Diuretics (thiazides): can predispose to hypocalcemia; monitor serum calcium levels.